Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma

Virchows Archiv

Volumn 465, Issue 1, 2014, Pages 79-88

  Arzt, Lisa ^a   Kothmaier, Hannelore ^a   Halbwedl, Iris ^a   Quehenberger, Franz ^a   Popper, Helmut H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Interferon gamma; Malignant pleural mesothelioma; Phosphorylated STAT1; SOCS1; STAT signaling

Indexed keywords

FORMALDEHYDE; GAMMA INTERFERON; PARAFFIN; PROTEIN HYDROLYSATE; SERINE; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TYROSINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER SURVIVOR; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA CELL LINE; ONCOGENE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE FIXATION; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; LUNG NEOPLASMS; MESOTHELIOMA; ONCOGENES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UP-REGULATION;

EID: 84904752120     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1584-8     Document Type: Article

References (51)

1. Vogelzang NJ, Porta C, Mutti L (2005) New agents in the management of advanced mesothelioma. Semin Oncol 32(3):336-350 (Pubitemid 40834490)
2. Shukla A, BosenbergMW, MacPherson MB, Butnor KJ, Heintz NH, Pass HI, Carbone M, Testa JR, Mossman BT (2009) Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol 175(5):2197-2206. doi:10.2353/ajpath.2009.090400
3. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT (2006) Cellular and molecular parameters of mesothelioma. J Cell Biochem 98(4):723-734. doi:10.1002/jcb.20828 (Pubitemid 43993391)
4. Nowak AK, Lake RA, Kindler HL, Robinson BW (2002) New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 29(1):82-96 (Pubitemid 34163539)
5. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, Menard O, Mignot P, Dabouis G, Douillard JY (1994) Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74(9):2460-2467 (Pubitemid 24320849)
6. Hand A, Pelin K,Mattson K, Linnainmaa K (1995) Interferon (IFN)- alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 6(1):77-82
7. Hand AM, Husgafvel-Pursiainen K, Pelin K, Vallas M, Suitiala T, Ekman A, Mattson M, Mattson K, Linnainmaa K (1992) Interferonalpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 3(6):687-694 (Pubitemid 23028312)
8. Hand AM, Husgafvel-Pursiainen K, Tammilehto L, Mattson K, Linnainmaa K (1991) Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines. Cancer Lett 58(3):205-210
9. Phan-Bich L, Buard A, Petit JF, Zeng L, Tenu JP, Chretien P, Monnet I, Boutin C, Bignon J, Lemaire G, Jaurand MC (1997) Differential responsiveness of human and rat mesothelioma cell lines to recombinant interferon-gamma. Am J Respir Cell Mol Biol 16(2):178-186. doi:10.1165/ajrcmb.16.2.9032125 (Pubitemid 127498239)
10. Zeng L, Buard A, Monnet I, Boutin C, Fleury J, Saint-Etienne L, Brochard P, Bignon J, Jaurand MC (1993) In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 55(3):515-520 (Pubitemid 23300607)
11. Buard A, Vivo C, Monnet I, Boutin C, Pilatte Y, Jaurand MC (1998) Human malignant mesothelioma cell growth: activation of janus kinase 2 and signal transducer and activator of transcription 1alpha for inhibition by interferon-gamma. Cancer Res 58(4):840-847 (Pubitemid 28099501)
12. Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117(Pt 8):1281-1283. doi:10.1242/jcs.00963 (Pubitemid 38559804)
13. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197(2):157-168. doi:10.1002/jcp.10364 (Pubitemid 37485244)
14. Reich NC, Liu L (2006) Tracking STAT nuclear traffic. Nat Rev Immunol 6(8):602-612. doi:10.1038/nri1885 (Pubitemid 44134093)
15. Sadzak I, SchiffM, Gattermeier I, Glinitzer R, Sauer I, Saalmuller A, Yang E, Schaljo B, Kovarik P (2008) Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain. Proc Natl Acad Sci USA 105(26): 8944-8949. doi:10.1073/pnas.0801794105
16. Stephanou A, Latchman DS (2005) Opposing actions of STAT-1 and STAT-3. Growth Factors 23(3):177-182. doi :10.1080/08977190500178745
17. Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H, Comin CE, Murer B, Cagle PT, Attanoos R, Gibbs AR, Galateau-Salle F, Popper HH (2008) EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 63(4):345-351. doi:10.1136/thx.2007.085241 (Pubitemid 351497948)
18. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4):945-954 (Pubitemid 35177340)
19. Wormald S, Hilton DJ (2004) Inhibitors of cytokine signal transduction. J Biol Chem 279(2):821-824. doi:10.1074/jbc.R300030200 (Pubitemid 38082600)
20. Espert L, Dusanter-Fourt I, Chelbi-Alix MK (2005) Negative regulation of the JAK/STAT: pathway implication in tumorigenesis. Bull Cancer 92(10):845-857 (Pubitemid 41604953)
21. Klampfer L (2008) The role of signal transducers and activators of transcription in colon cancer. Front Biosci 13:2888-2899
22. Pass HI, Stevens EJ, Oie H, TsokosMG, Abati AD, Fetsch PA,Mew DJ, Pogrebniak HW, Matthews WJ (1995) Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 59(4):835- 844
23. Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A (1987) Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res 47(12):3199-3205 (Pubitemid 17082649)
24. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT (2010) Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 9:314. doi:10.1186/1476- 4598-9-314
25. Ordonez NG (2007)What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 38(1):1-16
26. Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Hofler H (2007) Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 211(3):370-378 (Pubitemid 46172713)
27. Kothmaier H, Rohrer D, Stacher E, Quehenberger F, Becker KF, Popper HH (2011) Comparison of formalin-free tissue fixatives: a proteomic study testing their application for routine pathology and research. Arch Pathol Lab Med 135(6):744-752
28. Shaffer J (1986) Modified sequentially rejective multiple test procudures. J Am Stat Assoc 81(395):826-831
29. Arzt L, Kothmaier H, Quehenberger F, Halbwedl I, Popper HH (2011) STAT signalling in malignant mesothelioma: is there a regulatory effect of microRNAs? Mag Eur Med Oncol 4(1):38-42
30. Ma J, Cao X (2006) Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal 18(8):1117-1126 (Pubitemid 43674037)
31. Wenta N, Strauss H, Meyer S, Vinkemeier U (2008) Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci USA 105(27):9238-9243
32. McBride KM, Banninger G, McDonald C, Reich NC (2002) Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha. Embo J 21(7):1754-1763 (Pubitemid 34614631)
33. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR (1997) Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278(5343):1630-1632
34. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000-5005. doi:10.1158/1078-0432.ccr-08-0746
35. Kanwar RK, Cheung CH, Chang JY, Kanwar JR (2010) Recent advances in anti-survivin treatments for cancer. Curr Med Chem 17(15):1509-1515
36. Zimmerman M, Yang D, Hu X, Liu F, Singh N, Browning D, Ganapathy V, Chandler P, Choubey D, Abrams SI, Liu K (2010) IFN-gamma upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. PLoS One 5(11):e14076. doi:10.1371/journal.pone.0014076
37. BerishajM, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, GeraldWL, Bornmann W, Bromberg JF (2007) Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9(3):R32. doi:10.1186/bcr1680
38. Braun DA, Fribourg M, Sealfon SC (2013) Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J Biol Chem 288(5): 2986-2993. doi:10.1074/jbc.M112.386573
39. Russell MA, Cooper AC, Dhayal S, Morgan NG (2013) Differential effects of interleukin-13 and interleukin-6 on Jak/STATsignaling and cell viability in pancreatic beta-cells. Islets 5 (2)
40. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY,Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ, Qin LX (2013) MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway. Hepatology. doi:10.1002/hep.26305
41. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109(9):1139-1142. doi:10.1172/jci15617
42. Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101(4):1535-1542. doi:10.1182/blood- 2002-07-2130
43. QingY, Stark GR (2004) Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 279(40):41679-41685. doi:10.1074/jbc.M406413200
44. Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282(28):20059-20063. doi:10.1074/jbc. R700016200 (Pubitemid 47099977)
45. Liao J, Fu Y, Shuai K (2000) Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. Proc Natl Acad Sci USA 97(10): 5267-5272 (Pubitemid 30313707)
46. Ungureanu D, Vanhatupa S, Kotaja N, Yang J, Aittomaki S, Janne OA, Palvimo JJ, Silvennoinen O (2003) PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 102(9):3311-3313. doi:10. 1182/blood-2002-12-3816
47. Lee JH, Park SM, Kim OS, Lee CS,Woo JH, Park SJ, Joe EH, Jou I (2009) Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma- stimulated brain astrocytes. Mol Cell 35(6):806-817. doi:10.1016/j.molcel.2009.07.021
48. Madonna S, Scarponi C, De Pita O, Albanesi C (2008) Suppressor of cytokine signaling 1 inhibits IFN-gamma inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation. FASEB J 22(9):3287-3297
49. Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, Becknell B, CarsonWE 3rd (2010) Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer 10:142. doi:10.1186/1471-2407-10-142
50. Klampfer L (2006) Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6(2):107-121
51. Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T (2013) SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer 132(2):459-471. doi:10.1002/ijc.27611